IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL5.67▲ 0.45% USD/MXN18.52▼ 0.42% USD/CLP994.16▼ 0.13% USD/COP3,302▲ 0.70% USD/PEN3.40▼ 0.16% USD/ARS1,544▼ 0.11% USD/UYU40.59▲ 2.33% USD/PYG6,196▲ 2.33% USD/BOB11.59▼ 0.37% USD/DOP60.59▲ 1.85% USD/CRC442.74▼ 0.10% USD/GTQ7.64▲ 2.06% USD/HNL26.91▲ 2.15% USD/NIO36.62▲ 2.73% USD/VES909.35▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.69▲ 1.39% USD/TTD6.75▲ 1.58% EUR/BRL6.25▲ 0.93% BRENT 95.84 ▲ 0.02% WTI 88.56 ▼ 0.20% IRON ORE 161.91 — — COPPER 6.09 ▼ 1.50% GOLD 3,886 ▲ 0.03% SILVER 49.12 ▼ 1.70% SOY 1,232 ▲ 0.37% CORN 445.50 ▲ 0.68% WHEAT 593.25 ▲ 1.54% COFFEE 279.25 ▼ 0.34% SUGAR 18.40 ▲ 0.99% ORANGE JUICE 136.85 ▼ 2.91% COTTON 79.02 ▲ 0.44% COCOA 5,123 ▲ 1.13% BEEF 224.80 ▲ 2.70% CATTLE 335.35 ▼ 0.10% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 ▲ 1.34% VALE3 63.50 ▼ 0.70% ITUB4 42.27 ▲ 1.42% BBDC4 14.52 ▲ 1.40% ABEV3 15.79 ▲ 0.25% BBAS3 15.10 ▼ 2.45% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 ▼ 2.27% RENT3 30.07 ▲ 1.66% AZZA3 15.91 ▼ 5.86% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 ▼ 1.63% RANI3 8.18 — 0.00% CSNA3 3.72 ▼ 12.06% IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL 5.67 ▲ 0.45% USD/MXN 18.52 ▼ 0.42% USD/CLP 994.16 ▼ 0.13% USD/COP 3,302 ▲ 0.70% USD/PEN 3.40 ▼ 0.16% USD/ARS 1,544 ▼ 0.11% USD/UYU 40.59 ▲ 2.33% USD/PYG 6,196 ▲ 2.33% USD/BOB 11.59 ▼ 0.37% USD/DOP 60.59 ▲ 1.85% USD/CRC 442.74 ▼ 0.10% USD/GTQ 7.64 ▲ 2.06% USD/HNL 26.91 ▲ 2.15% USD/NIO 36.62 ▲ 2.73% USD/VES 909.35 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.69 ▲ 1.39% USD/TTD 6.75 ▲ 1.58% EUR/BRL 6.25 ▲ 0.93% BRENT 95.84 ▲ 0.02% WTI 88.56 ▼ 0.20% IRON ORE 161.91 — — COPPER 6.09 ▼ 1.50% GOLD 3,886 ▲ 0.03% SILVER 49.12 ▼ 1.70% SOY 1,232 ▲ 0.37% CORN 445.50 ▲ 0.68% WHEAT 593.25 ▲ 1.54% COFFEE 279.25 ▼ 0.34% SUGAR 18.40 ▲ 0.99% ORANGE JUICE 136.85 ▼ 2.91% COTTON 79.02 ▲ 0.44% COCOA 5,123 ▲ 1.13% BEEF 224.80 ▲ 2.70% CATTLE 335.35 ▼ 0.10% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 ▲ 1.34% VALE3 63.50 ▼ 0.70% ITUB4 42.27 ▲ 1.42% BBDC4 14.52 ▲ 1.40% ABEV3 15.79 ▲ 0.25% BBAS3 15.10 ▼ 2.45% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 ▼ 2.27% RENT3 30.07 ▲ 1.66% AZZA3 15.91 ▼ 5.86% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 ▼ 1.63% RANI3 8.18 — 0.00% CSNA3 3.72 ▼ 12.06%
since 2009
Saturday, November 14, 2026

Brazil Latest News

Terminal Patient is Cancer-Free Through Brazilian Genetic Therapy

By · · 3 min read

RIO DE JANEIRO, BRAZIL – The man will be released from hospital free from cancer symptoms, due to a Brazilian method based on a gene therapy technique discovered abroad and known as CART-Cell.

According to the doctors, 63-year-old Vamberto, a retired civil servant from Minas Gerais, responded well to the treatment. He suffered from lymphoma and took morphine daily. His life expectancy was one year.

2
A Brazilian terminal patient with cancer will be discharged from hospital following a successful gene therapy employed for the first time in Latin America.
RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

However, four days after the treatment, he stopped feeling the severe pain caused by the disease; a week later he was walking again and the cancer went into remission.

“Miraculous”

“This first treatment stage was miraculous,” said hematologist Dimas Tadeu Covas, the coordinator of the Center for Cell Therapy (CTC-Fapesp) and the National Institute of Stem Cells and Cell Therapy, supported by CNPq and the Ministry of Health.

“There is no more evidence of the disease, he had several lymph nodes throughout his body. They are all gone. He had unbearable pain, depended on morphine every day. This is a story with a very happy ending.”

The researchers of the Cell Therapy Center (CTC-Fapesp-USP) of the Hemocentro, connected to the Hospital das Clínicas de Ribeirão Preto, said that the patient is “virtually” free of the disease, but are not talking about a cure yet because the final diagnosis can only be given after five years of follow-up. Technically, the exams point to a “cancer remission”.

Took part in the research

Before coming to the interior of São Paulo, Vamberto tried chemotherapy and radiotherapy, but his body did not respond well to either of them.

In palliative treatment, with the maximum dosage of morphine, he was admitted on September 9th to the Hospital das Clínicas in Ribeirão Preto in great pain, weight loss and difficulty walking.

The tumor had spread to the bones.

His prognosis, according to the doctors, was of less than one year of life. As a final attempt, the doctors included the patient in a “research protocol” and tested the new therapy, so far never used in Brazil.

Treatment

USP researchers – assisted by the Foundation for Research Support of the State of São Paulo (FAPESP) and by the National Research Council (CNPq) – have developed their own procedure for applying the CART-Cell technique, which was developed in the USA, is still recent, in its research stage and is not accessible to the public.

In the USA, commercial therapies have already been approved and may cost over US$475,000.

CART-Cell is a form of gene therapy already used in the United States, Europe, China, and Japan. It consists of the manipulation of immune system cells to fight cancer-causing cells.

CART-Cell’s strategy is to enable body defense cells (T lymphocytes) with receptors capable of identifying the tumor.

The attack is continuous and specific and, in most cases, a single dose is sufficient.

1
CART-Cell is a form of gene therapy and consists of the manipulation of immune system cells to fight cancer-causing cells.

How

Renato Luiz Cunha, one of the study’s coordinators, explained that gene therapy can modify the body’s defense cells to fight those that cause cancer.

“The cells will grow in the patient’s body and will fight the tumor,” said Cunha. “And we have developed a fully Brazilian technology, a treatment that costs more than US$1 million in the United States. We hope it can be accessible to all SUS patients in the future.”

In 2018, Cunha was awarded a prize by the American Association of Hematology (ASH) in the United States to develop this study in Brazil.

Source: G1, Jornal da USP

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.